T
Takanori Matsuki
Researcher at Osaka University
Publications - 34
Citations - 183
Takanori Matsuki is an academic researcher from Osaka University. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 5, co-authored 25 publications receiving 75 citations.
Papers
More filters
Journal ArticleDOI
Antitumor effect of Batf2 through IL-12 p40 up-regulation in tumor-associated macrophages.
Hisashi Kanemaru,Fumihiro Yamane,Kiyoharu Fukushima,Takanori Matsuki,Takahiro Kawasaki,Isao Ebina,Kanako Kuniyoshi,Hiroki Tanaka,Kenta Maruyama,Kazuhiko Maeda,Takashi Satoh,Shizuo Akira +11 more
TL;DR: It is found that basic leucine zipper transcription factor ATF-like 2 (Batf2) has an antitumor effect through the up-regulation of IL-12 p40 in tumor-associated macrophages, which eventually induces CD8+ T-cell activation and accumulation within the tumor.
Journal ArticleDOI
Long-Term Treatment Outcome of Progressive Mycobacterium Avium Complex Pulmonary Disease.
Kiyoharu Fukushima,Seigo Kitada,Yuko Abe,Yuji Yamamoto,Takanori Matsuki,Hiroyuki Kagawa,Yohei Oshitani,Kazuyuki Tsujino,Kenji Yoshimura,Mari Miki,Keisuke Miki,Hiroshi Kida +11 more
TL;DR: Standardized intensive multidrug treatment reduces disease progression and persistence in progressive Mycobacterium avium complex pulmonary disease and highlights the need for early diagnosis and treatment.
Journal ArticleDOI
First line treatment selection modifies disease course and long-term clinical outcomes in Mycobacterium avium complex pulmonary disease.
Kiyoharu Fukushima,Seigo Kitada,Sho Komukai,Tomoki Kuge,Takanori Matsuki,Hiroyuki Kagawa,Kazuyuki Tsujino,Mari Miki,Keisuke Miki,Hiroshi Kida +9 more
TL;DR: In this paper, a single-centred retrospective cohort study was conducted to evaluate the long-term outcomes in 295 patients with MAC-PD following first line treatment with standard (RFP, EB, clarithromycin [CAM]) or alternative (EB and CAM with or without fluoroquinolones (FQs) or RFP, CAM, and FQs).
Journal ArticleDOI
Acute lung injury after plasma exchange in a patient with anti-MDA5 antibody-positive, rapidly progressive, interstitial lung disease:A case report.
Hiroyuki Kagawa,Kazuyuki Tsujino,Yuji Yamamoto,Ami Iwai,Reina Hara,Takanori Matsuki,Kiyoharu Fukushima,Yohei Oshitani,Kenji Yoshimura,Mari Miki,Keisuke Miki,Seigo Kitada,Masahide Mori,Hiroshi Kida +13 more
TL;DR: This case supports the idea that the presence of ILD could increase a risk for TRALI and therefore the eligibility for PE therapy of anti-MDA5 Ab-positive RP-ILD patients should be carefully evaluated given the risk of acute lung injury.
Journal ArticleDOI
The impact of adjuvant surgical treatment of nontuberculous mycobacterial pulmonary disease on prognosis and outcome.
Kiyoharu Fukushima,Mari Miki,Yuki Matsumoto,Emi Uda,Yuji Yamamoto,Yuya Kogita,Yuko Kagawa,Takanori Matsuki,Hiroyuki Kagawa,Yohei Oshitani,Daisuke Motooka,Kazuyuki Tsujino,Kenji Yoshimura,Keisuke Miki,Akio Hayashi,Shota Nakamura,Seigo Kitada,Yukiyasu Takeuchi,Hiroshi Kida +18 more
TL;DR: NTM-PD patients who underwent adjuvant lung resection experienced overall favorable outcomes and achieved sputum culture conversion more frequently and long-term mortality may have been reduced by this procedure, and the level of GPL core antibody was shown to be a good clinical indicator of disease activity after surgery.